JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Madrigal Pharmaceuticals Inc

Suletud

SektorTervishoid

424.5 1.94

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

413

Max

424.77

Põhinäitajad

By Trading Economics

Sissetulek

31M

-42M

Müük

76M

213M

Aktsiakasum

-1.9

Kasumimarginaal

-19.869

Töötajad

528

EBITDA

31M

-39M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+21.75% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. nov 2025

Turustatistika

By TradingEconomics

Turukapital

2.9B

9.8B

Eelmine avamishind

422.56

Eelmine sulgemishind

424.5

Uudiste sentiment

By Acuity

50%

50%

163 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Madrigal Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. okt 2025, 20:49 UTC

Tulu

Correction to Thermo Fisher Article on Oct. 22

23. okt 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. okt 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. okt 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. okt 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -2-

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. okt 2025, 22:17 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. okt 2025, 21:41 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. okt 2025, 21:05 UTC

Tulu

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. okt 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. okt 2025, 20:35 UTC

Tulu

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. okt 2025, 20:28 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. okt 2025, 20:15 UTC

Market Talk
Tulu

Global Commodities Roundup: Market Talk

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Adj EPS $1.71

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Sales $5.52B

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q EPS $1.67

23. okt 2025, 20:09 UTC

Tulu

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. okt 2025, 20:07 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

23. okt 2025, 20:07 UTC

Market Talk
Tulu

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. okt 2025, 20:07 UTC

Tulu

Blackstone Looks to IPOs for Investment Exits -- Update

23. okt 2025, 20:05 UTC

Tulu

Intel 3Q Gross Margin 38.2% >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. okt 2025, 20:04 UTC

Tulu

Intel: 4Q Guidance Excludes Altera >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Sees 4Q Adj EPS 8c >INTC

Võrdlus sarnastega

Hinnamuutus

Madrigal Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

21.75% tõus

12 kuu keskmine prognoos

Keskmine 506.43 USD  21.75%

Kõrge 590 USD

Madal 266 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Madrigal Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

14

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

263.2 / 277.1Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

163 / 371 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat